Galecto ditches high doses in phase II trial

An independent data safety monitoring board recommends that Galecto ditches the highest dose of the firm's drug GB0139 in a phase 2b study against idiopathic pulmonary fibrosis.

Galecto President & CEO Hans Schambye. | Photo: Henriette Dan Bonde / PR

After an independent data safety monitoring board has looked through preliminary data from Galecto's phase IIb study of idiopathic pulmonary fibrosis (IPF), the company has been forced to rearrange the trial on the basis of the monitoring board's recommendations, according to a press statement.

The recommendation states that Galecto should stop dosing the drug GB0139 in its highest dose, 10 mg, since an imbalance has been observed in the various patient groups in the study. Namely among the patients receiving the lowest dose, 3 mg, in combination with existing standard treatments for IPF and the drugs nintedanib and pirfenidone.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs